

Andrea Vergallo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2494555/andrea-vergallo-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89
papers

2,059
citations

23
h-index

43
g-index

108
ext. papers

3,208
ext. citations

4.4
avg, IF

5.01
L-index

#	Paper	IF	Citations
89	Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	1
88	Toward Noninvasive Brain Stimulation 2.0 in Alzheimer's Disease.. <i>Ageing Research Reviews</i> , 2021 , 75, 101555	12	2
87	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis.. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 748198	5.3	1
86	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6
85	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021 , 185, 108081	5.5	12
84	The β Secretase BACE1 in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021 , 89, 745-756	7.9	107
83	Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2021 , 8, 306-312	3.8	5
82	Aptamer prediction of brain amyloid- β status in cognitively normal individuals at risk for Alzheimer's disease. <i>PLoS ONE</i> , 2021 , 16, e0243902	3.7	1
81	MiRNA-15b and miRNA-125b are associated with regional A β PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021 , 11, 78	8.6	6
80	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021 , 18, 27-48	4.2	3
79	Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2021 , 8, 513-519	3.8	4
78	Plasma β Secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021 , 17, 629-640	1.2	4
77	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. <i>Neurobiology of Aging</i> , 2021 , 103, 78-97	5.6	3
76	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021 , 17, 580-589	15	25
75	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 949-967	4.3	0
74	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. <i>Ageing Research Reviews</i> , 2021 , 69, 101346	12	17
73	The Amyloid- β Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	63

72	Association of plasma A β ₄₀ /A β ₄₂ ratio and brain A β accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021 , 107, 57-69	5.6	1
71	Association of plasma YKL-40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041753	1.2	
70	Aging and sex impact plasma NFL and t-Tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041792	1.2	
69	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045832	1.2	
68	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046014	1.2	
67	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e046105	1.2	
66	In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 93, 98-108	5.6	10
65	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 421-441	3.8	19
64	Early Detection of Mild Cognitive Impairment (MCI) in Primary Care. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2020 , 7, 165-170	3.8	21
63	Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2020 , 7, 171-178	3.8	12
62	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 88, 83-90	5.6	3
61	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020 , 94, e30-e41	6.5	13
60	Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies. <i>Journal of Prevention of Alzheimer's Disease, The</i> , 2020 , 7, 158-164	3.8	8
59	Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 130	9	2
58	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2020 , 17, 543-559	4.2	6
57	Association of plasma YKL-40 with brain amyloid levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020 , 96, 22-32	5.6	4
56	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020 , 90, 43-59	5.6	12
55	microRNA-Based Biomarkers in Alzheimer's Disease (AD). <i>Frontiers in Neuroscience</i> , 2020 , 14, 585432	5.1	28

54	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 147	9	8
53	Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	5
52	The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020 , 7, 294-298	3.8	3
51	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020 , 11, 456	8.4	87
50	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019 , 83, 42-53	5.6	23
49	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 615-629	4.3	28
48	Blood-based diagnostics of Alzheimer's disease. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 613-623	3.8	8
47	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019 , 16, 593-600	4.2	20
46	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 764-775	1.2	86
45	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 940-950	1.2	31
44	Commentary: Development of the Blood-Based Alzheimer's Disease Liquid Biopsy. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019 , 6, 182-184	3.8	1
43	Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019 , 32, 164-169	3.8	6
42	Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharmacology. <i>Frontiers in Pharmacology</i> , 2019 , 10, 310	5.6	23
41	The Alzheimer Precision Medicine Initiative. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 1-24	4.3	48
40	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 15	9	17
39	Time for the systems-level integration of aging: Resilience enhancing strategies to prevent Alzheimer's disease. <i>Progress in Neurobiology</i> , 2019 , 181, 101662	10.9	26
38	Brain A β load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1274-1285	1.2	9
37	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 553-562	6	5

36	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019 , 21, 177-191	5.7	13
35	LONGITUDINAL EFFECT OF BIOLOGICAL VARIABLES ON PLASMA NFL AND T-TAU CONCENTRATIONS ON SUBJECTIVE MEMORY COMPLAINERS (INSIGHT-PREAD-COHORT): A 3-YEAR FOLLOW-UP STUDY 2019 , 15, P213		
34	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019 , 15, 465-476	1.2	127
33	Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. <i>Journal of Prevention of Alzheimer's Disease</i> , 2019 , 6, 2-15	3.8	61
32	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018 , 130, 331-365	10.2	60
31	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S47-S105	4.3	84
30	Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018 , 33, 35-41	2.5	11
29	Association of cerebrospinal fluid Bsynuclein with total and phospho-tau protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1623-1631	1.2	30
28	Reply: Optimal use of cholinergic drugs in Alzheimer's disease. <i>Brain</i> , 2018 , 141, e69	11.2	
27	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1204-1215	1.2	40
26	Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. <i>Frontiers in Neuroendocrinology</i> , 2018 , 50, 31-51	8.9	29
25	P4-072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL 2018 , 14, P1461-P1462		
24	The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology. <i>Neurodegenerative Diseases</i> , 2018 , 18, 302-309	2.3	8
23	P2-237: ASSOCIATION OF CSF ALPHA-SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS 2018 , 14, P762-P762		
22	O3-09-02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOID-PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P1036-P1037		
21	P4-186: INNOVATIVE BIOMARKER-GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA 2018 , 14, P1510-P1511		
20	P2-246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKL-40 CONCENTRATIONS IN AMYLOID-PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P767-P768		
19	P2-249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS 2018 , 14, P768-P769		

18	P2-355: CORRELATION OF FUNCTIONAL MRI CONNECTOMES WITH PATHOPHYSIOLOGICAL ALZHEIMER'S PLASMA BIOMARKERS AND RISK FACTORS IN SUBJECTIVE MEMORY COMPLAINERS 2018 , 14, P824-P825		
17	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. <i>Brain</i> , 2018 , 141, 1917-1933	11.2	492
16	Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimer's disease. <i>Endocrine</i> , 2017 , 55, 981-984	4	15
15	A single center study: A β 2/p-Tau CSF ratio to discriminate AD from FTD in clinical setting. <i>Neurological Sciences</i> , 2017 , 38, 1791-1797	3.5	13
14	Treatment of epilepsy in patients with Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 309-318	4.3	14
13	Migraine features in migraineurs with and without anxiety-depression symptoms: a hospital-based study. <i>Clinical Neurology and Neurosurgery</i> , 2015 , 132, 74-8	2	30
12	RE response to: "Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome". <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 427	3.6	2
11	Clinical features associated with ictal osmophobia in migraine. <i>Neurological Sciences</i> , 2015 , 36, 43-6	3.5	20
10	Sexual headache: two familiar orgasmic headache cases and review of the literature. <i>Acta Neurologica Belgica</i> , 2015 , 115, 757-8	1.5	0
9	Occurrence of Takotsubo syndrome in a patient with Parkinson's disease after entacapone add-on. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1313-4	3.6	10
8	Localized calcific hematoma of the scalp presenting as a nummular-like headache: a case report. <i>Headache</i> , 2014 , 54, 370-2	4.2	8
7	Affective theory of mind in patients with Parkinson's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2013 , 67, 273-6	6.2	23
6	How aware are migraineurs of their triggers?. <i>Headache</i> , 2013 , 53, 834-7	4.2	21
5	Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115, 1105-6	2	
4	Triggers in allodynic and non-allodynic migraineurs. A clinic setting study. <i>Headache</i> , 2013 , 53, 152-160	4.2	23
3	A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 691-4	1.7	59
2	Bilateral thalamic infarct caused by spontaneous vertebral artery dissection in pre-eclampsia with HELLP syndrome: a previously unreported association. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012 , 21, 914.e9-10	2.8	10
1	Peri-ictal prolonged atrial fibrillation after generalized seizures: description of a case and etiopathological considerations. <i>Epilepsy and Behavior</i> , 2012 , 23, 377-8	3.2	10

